Published in Prostate on February 15, 2002
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Mechanisms of the development of androgen independence in prostate cancer. World J Urol (2005) 1.23
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res (2010) 1.22
Clusterin and chemoresistance. Adv Cancer Res (2009) 1.14
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res (2012) 1.14
Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol (2005) 1.12
Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol (2014) 1.11
Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. Neoplasia (2007) 1.05
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
Clusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78. PLoS One (2013) 0.93
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 0.93
Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91
Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res (2011) 0.91
Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. Nat Commun (2014) 0.90
Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci (2013) 0.89
Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. Prostate (2014) 0.89
Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer (2004) 0.87
Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics Clin Appl (2008) 0.87
Genetic background influences murine prostate gene expression: implications for cancer phenotypes. Genome Biol (2007) 0.86
Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist (2011) 0.85
Androgens and prostate cancer. World J Urol (2003) 0.84
Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs (2002) 0.84
Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. Prostate Cancer (2011) 0.82
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Cancer Med (2013) 0.80
Acute sex steroid withdrawal increases cholesterol efflux capacity and HDL-associated clusterin in men. Steroids (2012) 0.80
Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (2010) 0.80
Androgen receptor variants and prostate cancer in humanized AR mice. J Steroid Biochem Mol Biol (2007) 0.79
Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer (2010) 0.79
Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol (2010) 0.79
mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. J Cell Physiol (2012) 0.78
Potential use of custirsen to treat prostate cancer. Onco Targets Ther (2013) 0.78
Clinical significance of clusterin expression in pancreatic adenocarcinoma. World J Surg Oncol (2012) 0.77
Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget (2014) 0.77
Differential age-associated regulation of clusterin expression in prostate lobes of brown Norway rats. Prostate (2009) 0.76
Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Mol Med (2016) 0.75
Cytoskeleton reorganization as an alternative mechanism of store-operated calcium entry control in neuroendocrine-differentiated cells. PLoS One (2012) 0.75
Clusterin silencing sensitizes pancreatic cancer MIA-PaCa-2 cells to gmcitabine via regulation of NF-kB/Bcl-2 signaling. Int J Clin Exp Med (2015) 0.75
A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects. Br J Clin Pharmacol (2017) 0.75
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
A comparison of two time intervals for test-retest reliability of health status instruments. J Clin Epidemiol (2003) 3.65
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol (2013) 2.59
The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. J Bone Joint Surg Am (2005) 2.56
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU Int (2013) 2.38
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Beliefs and attitudes of members of the American Academy of Orthopaedic Surgeons regarding the treatment of anterior cruciate ligament injury. Arthroscopy (2003) 2.06
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology. J Magn Reson Imaging (2006) 1.94
Bacterial sepsis after prostate biopsy--a new perspective. Urology (2009) 1.91
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst (2005) 1.90
A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.85
Stat3 promotes metastatic progression of prostate cancer. Am J Pathol (2008) 1.85
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res (2004) 1.81
Phyllodes tumor of the prostate: long-term followup study of 23 cases. J Urol (2004) 1.77
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol (2004) 1.76
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol (2002) 1.67
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res (2009) 1.66
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther (2004) 1.63
High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res (2013) 1.58
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem (2007) 1.55
Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs (2002) 1.54
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer. BJU Int (2007) 1.52
Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer. Oncol Nurs Forum (2003) 1.50
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res (2004) 1.44
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate (2004) 1.40
Prostate specific antigen: an updated review. Can J Urol (2003) 1.39
A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int (2007) 1.38
Measuring improvement following total hip and knee arthroplasty using patient-based measures of outcome. J Bone Joint Surg Am (2005) 1.37
Chondral resurfacing of articular cartilage defects in the knee with the microfracture technique. Surgical technique. J Bone Joint Surg Am (2006) 1.32
Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res (2011) 1.28
RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One (2009) 1.28
Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res (2005) 1.26
Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys (2013) 1.25
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Measurement of shoulder activity level. Clin Orthop Relat Res (2005) 1.24
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res (2008) 1.21
Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res (2002) 1.20
Loss of PTEN is associated with progression to androgen independence. Prostate (2006) 1.20
Variation in orthopaedic surgeons' perceptions about the indications for rotator cuff surgery. J Bone Joint Surg Am (2005) 1.19
Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology (2007) 1.19
Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol (2007) 1.19
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.18
Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res (2012) 1.17
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int (2008) 1.17
Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res (2010) 1.16
Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res (2012) 1.16
Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int (2011) 1.15
Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res (2004) 1.13
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther (2013) 1.12
Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer. Cancer Nurs (2007) 1.12
Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res (2010) 1.12
Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer (2008) 1.12
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 1.11
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 1.07
Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. J Urol (2013) 1.06
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. Cancer Res (2008) 1.06
Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem (2006) 1.06
Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential. J Urol (2002) 1.05
Poly-gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes Cancer (2012) 1.05
Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol (2005) 1.05
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A (2014) 1.04
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol (2014) 1.04
Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. Prostate (2004) 1.04
Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci (2013) 1.04